Logo image
Beam F3 and 5.5 cm targeting show similar efficacy in rTMS treatment of depression: a randomized trial
Abstract   Open access   Peer reviewed

Beam F3 and 5.5 cm targeting show similar efficacy in rTMS treatment of depression: a randomized trial

Benjamin D. Pace, Brandon Neisewander, Patrick Ten Eyck, Aaron D. Boes and Nicholas T. Trapp
Brain stimulation, Vol.16(4), p.3
07/2023
DOI: 10.1016/j.brs.2023.07.011
url
https://doi.org/10.1016/j.brs.2023.07.011View
Published (Version of record) Open Access

Abstract

Background: The two most common targeting methods for localizing the left dorsolateral prefrontal cortex (DLPFC) treatment site in repetitive transcranial magnetic stimulation (rTMS) include the Beam F3 and 5.5 cm method. They localize to different regions. We conducted a clinical trial to compare efficacy between them, with a prospective, randomized, single-blind design in a naturalistic sample of patients with major depressive disorder (MDD) undergoing clinical treatment. Methods: 105 adult patients with MDD (mean age=43.2; range=18-73; 69 female) were randomized to receive rTMS to the Beam F3 or 5.5 cm target. Between group differences from pre- to post-treatment were evaluated with the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and clinician-administered Montgomery-Åsberg Depression Scale (MADRS). Primary treatment endpoint was completion of daily treatment series with at least 20 treatments. Subjects with head circumference >60 cm were excluded. Results: No statistically significant differences were discovered on any measure between the F3 and 5.5 cm groups, including percent change (PHQ-9: 39% vs. 39%, n=94, p=0.95; GAD-7: 34% vs. 27%, n=76, p=0.50; MADRS: 40% vs. 38%, n=67, p=0.83), response rates (PHQ-9: 37% vs. 43%; GAD-7: 27% vs. 30%; MADRS: 43% vs. 43%), and remission rates (PHQ-9: 22% vs. 21%; MADRS: 20% vs. 19%). The study was terminated following interim analysis due to futility. Conclusions: Similar antidepressant effects were observed with DLFPC rTMS using either the Beam F3 or 5.5 cm targeting method and may be equivalent for clinical use in patients with head circumference <60 cm. Comparison to MRI-based targeting requires further investigation.

Details

Metrics

43 Record Views
Logo image